{
    "thread": {
        "uuid": "965a91729ded8ec1e5c2156eee3b5f852dbf2e59",
        "url": "https://www.prnewswire.com/news-releases/mrns-investors-have-opportunity-to-lead-marinus-pharmaceuticals-inc-securities-fraud-lawsuit-302172214.html",
        "site_full": "www.prnewswire.com",
        "site": "prnewswire.com",
        "site_section": "https://www.prnewswire.com/sitemap-news.xml?page=1",
        "site_categories": [
            "media"
        ],
        "section_title": "",
        "title": "MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit",
        "title_full": "MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit",
        "published": "2024-06-13T23:53:00.000+03:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg?p=facebook",
        "performance_score": 0,
        "domain_rank": 193,
        "domain_rank_updated": "2024-06-11T13:07:50.000+03:00",
        "reach": null,
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "gplus": {
                "shares": 0
            },
            "pinterest": {
                "shares": 0
            },
            "linkedin": {
                "shares": 0
            },
            "stumbledupon": {
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "965a91729ded8ec1e5c2156eee3b5f852dbf2e59",
    "url": "https://www.prnewswire.com/news-releases/mrns-investors-have-opportunity-to-lead-marinus-pharmaceuticals-inc-securities-fraud-lawsuit-302172214.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "THE ROSEN LAW FIRM, P. A.",
    "published": "2024-06-13T23:53:00.000+03:00",
    "title": "MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit",
    "text": "NEW YORK , June 13, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS ) between March 17, 2021 and May 7, 2024 . Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 5, 2024 .\nTo join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.\nThe Rosen Law Firm is investigating the Allegations that Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding its Business Operations.\nAccording to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.\nPlaintiff alleges that on May 8, 2024 , Fierce Biotech published an article which illustrated the impact on the Company of the failure to meet the early stopping criteria in the RAISE trial. On this news, Marinus Pharmaceuticals' stock fell.\nWhat Now: You may be eligible to participate in the class action against Marinus Pharmaceuticals, Inc. The deadline to file a motion to be appointed as lead plaintiff is August 5, 2024 . A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, go to https://rosenlegal.com/case/marinus-pharmaceuticals-inc/\nAll representation is on a contingency fee basis. Shareholders pay no fees or expenses.\nAttorney Advertising. Prior results do not guarantee a similar outcome.\nContact Information:\nLaurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com\nSOURCE THE ROSEN LAW FIRM, P. A.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
        "Crime, Law and Justice"
    ],
    "webz_reporter": false,
    "external_links": [
        "https://rosenlegal.com/submit-form/?case_id=25735",
        "https://c212.net/c/link/?t=0&l=en&o=4190625-1&h=1472960059&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D25735&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D25735",
        "https://rosenlegal.com/case/marinus-pharmaceuticals-inc/",
        "https://c212.net/c/link/?t=0&l=en&o=4190625-1&h=3296151965&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com",
        "https://c212.net/c/link/?t=0&l=en&o=4190625-1&h=3827810670&u=https%3A%2F%2Frosenlegal.com%2Fcase%2Fmarinus-pharmaceuticals-inc%2F&a=https%3A%2F%2Frosenlegal.com%2Fcase%2Fmarinus-pharmaceuticals-inc%2F",
        "https://rosenlegal.com/submit-form/",
        "https://www.c212.net/c/link/?t=0&l=en&o=4190625-1&h=1472960059&u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D25735&a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D25735",
        "https://www.rosenlegal.com/submit-form/?case_id=25735",
        "https://www.c212.net/c/link/?t=0&l=en&o=4190625-1&h=3827810670&u=https%3A%2F%2Frosenlegal.com%2Fcase%2Fmarinus-pharmaceuticals-inc%2F&a=https%3A%2F%2Frosenlegal.com%2Fcase%2Fmarinus-pharmaceuticals-inc%2F",
        "https://www.c212.net/c/link/?t=0&l=en&o=4190625-1&h=3296151965&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com",
        "https://rosenlegal.com/case/marinus-pharmaceuticals-inc",
        "https://c212.net/c/link/",
        "https://www.rosenlegal.com/case/marinus-pharmaceuticals-inc/"
    ],
    "external_images": [],
    "entities": {
        "persons": [
            {
                "name": "phillip kim",
                "sentiment": "none"
            }
        ],
        "organizations": [
            {
                "name": "securities fraud lawsuit",
                "sentiment": "negative"
            },
            {
                "name": "rosen law firm",
                "sentiment": "negative"
            },
            {
                "name": "lead marinus pharmaceuticals, inc",
                "sentiment": "neutral"
            },
            {
                "name": "marinus pharmaceuticals, inc.",
                "sentiment": "none"
            }
        ],
        "locations": [
            {
                "name": "new york",
                "sentiment": "none"
            },
            {
                "name": "esq.",
                "sentiment": "none"
            }
        ]
    },
    "rating": null,
    "crawled": "2024-06-14T00:18:31.365+03:00",
    "updated": "2024-06-14T00:18:31.365+03:00"
}